Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.79
AMGN's Cash to Debt is ranked higher than
58% of the 917 Companies
in the Global Biotechnology industry.

( Industry Median: 20.79 vs. AMGN: 0.79 )
AMGN' s 10-Year Cash to Debt Range
Min: 0.27   Max: 8.25
Current: 0.79

0.27
8.25
Equity to Asset 0.35
AMGN's Equity to Asset is ranked higher than
56% of the 766 Companies
in the Global Biotechnology industry.

( Industry Median: 0.65 vs. AMGN: 0.35 )
AMGN' s 10-Year Equity to Asset Range
Min: 0.33   Max: 0.84
Current: 0.35

0.33
0.84
F-Score: 6
Z-Score: 2.29
M-Score: -2.50
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 31.56
AMGN's Operating margin (%) is ranked higher than
95% of the 825 Companies
in the Global Biotechnology industry.

( Industry Median: -65.07 vs. AMGN: 31.56 )
AMGN' s 10-Year Operating margin (%) Range
Min: -14.21   Max: 42.33
Current: 31.56

-14.21
42.33
Net-margin (%) 25.74
AMGN's Net-margin (%) is ranked higher than
95% of the 825 Companies
in the Global Biotechnology industry.

( Industry Median: -70.66 vs. AMGN: 25.74 )
AMGN' s 10-Year Net-margin (%) Range
Min: -25.2   Max: 34.22
Current: 25.74

-25.2
34.22
ROE (%) 20.54
AMGN's ROE (%) is ranked higher than
95% of the 862 Companies
in the Global Biotechnology industry.

( Industry Median: -21.70 vs. AMGN: 20.54 )
AMGN' s 10-Year ROE (%) Range
Min: -7.61   Max: 36.26
Current: 20.54

-7.61
36.26
ROA (%) 7.20
AMGN's ROA (%) is ranked higher than
92% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: -18.92 vs. AMGN: 7.20 )
AMGN' s 10-Year ROA (%) Range
Min: -5.69   Max: 26.89
Current: 7.2

-5.69
26.89
ROC (Joel Greenblatt) (%) 75.40
AMGN's ROC (Joel Greenblatt) (%) is ranked higher than
96% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: -215.73 vs. AMGN: 75.40 )
AMGN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -24.94   Max: 89.4
Current: 75.4

-24.94
89.4
Revenue Growth (%) 16.10
AMGN's Revenue Growth (%) is ranked higher than
88% of the 648 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. AMGN: 16.10 )
AMGN' s 10-Year Revenue Growth (%) Range
Min: 5.9   Max: 29.3
Current: 16.1

5.9
29.3
EBITDA Growth (%) 9.20
AMGN's EBITDA Growth (%) is ranked higher than
86% of the 626 Companies
in the Global Biotechnology industry.

( Industry Median: -8.10 vs. AMGN: 9.20 )
AMGN' s 10-Year EBITDA Growth (%) Range
Min: 1.1   Max: 25.3
Current: 9.2

1.1
25.3
EPS Growth (%) 11.50
AMGN's EPS Growth (%) is ranked higher than
87% of the 645 Companies
in the Global Biotechnology industry.

( Industry Median: -10.20 vs. AMGN: 11.50 )
AMGN' s 10-Year EPS Growth (%) Range
Min: 2.3   Max: 22.1
Current: 11.5

2.3
22.1
» AMGN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

AMGN Guru Trades in Q3 2013

Stanley Druckenmiller 231,000 sh (New)
Steven Cohen 63,283 sh (+187.92%)
Jeremy Grantham 2,668,851 sh (+29.16%)
Mario Gabelli 22,420 sh (+26.95%)
John Hussman 250,000 sh (+25%)
Vanguard Health Care Fund 10,758,455 sh (unchged)
Ray Dalio Sold Out
Paul Tudor Jones Sold Out
Pioneer Investments 696,092 sh (-2.31%)
Bill Frels 11,180 sh (-2.82%)
PRIMECAP Management 35,812,225 sh (-4.11%)
Mark Hillman 8,069 sh (-10.03%)
Ken Fisher 5,632 sh (-12.18%)
Dodge & Cox 160,052 sh (-38.73%)
Alan Fournier 90,000 sh (-41.94%)
Jim Simons 71,000 sh (-94.43%)
Manning & Napier Advisors, Inc 5,241 sh (-95.93%)
» More
Q4 2013

AMGN Guru Trades in Q4 2013

Ray Dalio 7,513 sh (New)
Joel Greenblatt 23,170 sh (New)
Paul Tudor Jones 7,697 sh (New)
Jim Simons 862,245 sh (+1114.43%)
Steven Cohen 751,083 sh (+1086.86%)
Jeremy Grantham 3,122,746 sh (+17.01%)
Mario Gabelli 23,620 sh (+5.35%)
Ken Fisher 5,837 sh (+3.64%)
Stanley Druckenmiller 231,000 sh (unchged)
Manning & Napier Advisors, Inc Sold Out
Pioneer Investments 694,971 sh (-0.16%)
PRIMECAP Management 35,508,354 sh (-0.85%)
Mark Hillman 7,912 sh (-1.95%)
Bill Frels 10,780 sh (-3.58%)
Dodge & Cox 136,620 sh (-14.64%)
Vanguard Health Care Fund 8,775,155 sh (-18.43%)
Alan Fournier 70,000 sh (-22.22%)
John Hussman 175,000 sh (-30%)
» More
Q1 2014

AMGN Guru Trades in Q1 2014

RS Investment Management 3,840 sh (New)
Louis Moore Bacon 3,450 sh (New)
Ken Fisher 49,887 sh (+754.67%)
Alan Fournier 150,000 sh (+114.29%)
Mario Gabelli 32,565 sh (+37.87%)
Pioneer Investments 783,138 sh (+12.69%)
Jeremy Grantham 3,290,249 sh (+5.36%)
Bill Frels 10,780 sh (unchged)
Ray Dalio Sold Out
Stanley Druckenmiller Sold Out
Joel Greenblatt Sold Out
Vanguard Health Care Fund 8,213,855 sh (-6.4%)
PRIMECAP Management 32,161,744 sh (-9.42%)
John Hussman 150,000 sh (-14.29%)
Dodge & Cox 105,757 sh (-22.59%)
Paul Tudor Jones 3,985 sh (-48.23%)
Jim Simons 333,349 sh (-61.34%)
Steven Cohen 13,665 sh (-98.18%)
» More
Q2 2014

AMGN Guru Trades in Q2 2014

John Buckingham 56,216 sh (New)
Joel Greenblatt 9,938 sh (New)
Daniel Loeb 450,000 sh (New)
Paul Tudor Jones 9,013 sh (+126.17%)
Mario Gabelli 60,335 sh (+85.28%)
Ken Fisher 85,316 sh (+71.02%)
Alan Fournier 236,000 sh (+57.33%)
Bill Frels 10,991 sh (+1.96%)
Louis Moore Bacon 3,450 sh (unchged)
Steven Cohen 238,008 sh (unchged)
RS Investment Management 3,840 sh (unchged)
Jeremy Grantham 3,260,920 sh (-0.89%)
PRIMECAP Management 31,853,844 sh (-0.96%)
Vanguard Health Care Fund 8,049,455 sh (-2%)
Jim Simons 310,645 sh (-6.81%)
Dodge & Cox 85,857 sh (-18.82%)
John Hussman 50,000 sh (-66.67%)
Pioneer Investments 142,948 sh (-81.75%)
» More
» Details

Insider Trades

Latest Guru Trades with AMGN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Hussman 2014-06-30 Reduce -66.67%0.93%$110.29 - $126.07 $ 137.419%50000
Daniel Loeb 2014-06-30 New Buy0.65%$110.29 - $126.07 $ 137.419%450000
Mario Gabelli 2014-06-30 Add 85.28%0.02%$110.29 - $126.07 $ 137.419%60335
Joel Greenblatt 2014-06-30 New Buy0.02%$110.29 - $126.07 $ 137.419%9938
PRIMECAP Management 2014-03-31 Reduce -9.42%0.46%$113.48 - $127.47 $ 137.414%32161744
Vanguard Health Care Fund 2014-03-31 Reduce -6.4%0.2%$113.48 - $127.47 $ 137.414%8213855
John Hussman 2014-03-31 Reduce -14.29%0.2%$113.48 - $127.47 $ 137.414%150000
Joel Greenblatt 2014-03-31 Sold Out 0.06%$113.48 - $127.47 $ 137.414%0
Ray Dalio 2014-03-31 Sold Out 0.01%$113.48 - $127.47 $ 137.414%0
Mario Gabelli 2014-03-31 Add 37.87%0.01%$113.48 - $127.47 $ 137.414%32565
Dodge & Cox 2014-03-31 Reduce -22.59%$113.48 - $127.47 $ 137.414%105757
Vanguard Health Care Fund 2013-12-31 Reduce -18.43%0.76%$106.28 - $118.688 $ 137.421%8775155
John Hussman 2013-12-31 Reduce -30%0.45%$106.28 - $118.688 $ 137.421%175000
Joel Greenblatt 2013-12-31 New Buy0.06%$106.28 - $118.688 $ 137.421%23170
Ray Dalio 2013-12-31 New Buy0.01%$106.28 - $118.688 $ 137.421%7513
John Hussman 2013-09-30 Add 25%0.3%$95.81 - $117.521 $ 137.427%250000
PRIMECAP Management 2013-09-30 Reduce -4.11%0.22%$95.81 - $117.521 $ 137.427%35812225
Ray Dalio 2013-09-30 Sold Out 0.07%$95.81 - $117.521 $ 137.427%0
Dodge & Cox 2013-09-30 Reduce -38.73%0.01%$95.81 - $117.521 $ 137.427%160052
Mario Gabelli 2013-09-30 Add 26.95%$95.81 - $117.521 $ 137.427%22420
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Amgen Inc

Mario Gabelli Comments on Amgen Inc. - Jan 06, 2014

Amgen Inc. (0.2%) (AMGN - $111.94 - NASDAQ)(AMGN) is one of the largest biotechnology companies in the world, with medicines for cancer, kidney dialysis, osteoporosis, and other conditions. Given its large size and mature product portfolio, revenue growth has slowed, but the company has been able to cut costs and repurchase shares to sustain double digit earnings per share growth. Earlier this year, Amgen offered to acquire Onyx Pharmaceuticals Inc. (less than 0.1%) to bolster its oncology portfolio, with Nexavar for liver cancer and Kyprolis for blood cancers. On Aug 25, after a brief auction, Amgen agreed to pay $125 per share, or $10.4 billion, for Onyx. While initially dilutive to earnings, this acquisition provides significant visibility into Amgen's future, with two blockbuster drugs that could eventually generate over $5 billion in annual sales. 

 

From Mario Gabelli (Trades, Portfolio)'s third quarter 2013 commentary.

Check out Mario Gabelli latest stock trades

Top Ranked Articles about Amgen Inc

Mario Gabelli Comments on Amgen Inc.
Amgen Inc. (0.2%) (AMGN - $111.94 - NASDAQ)(AMGN) is one of the largest biotechnology companies in the world, with medicines for cancer, kidney dialysis, osteoporosis, and other conditions. Given its large size and mature product portfolio, revenue growth has slowed, but the company has been able to cut costs and repurchase shares to sustain double digit earnings per share growth. Earlier this year, Amgen offered to acquire Onyx Pharmaceuticals Inc. (less than 0.1%) to bolster its oncology portfolio, with Nexavar for liver cancer and Kyprolis for blood cancers. On Aug 25, after a brief auction, Amgen agreed to pay $125 per share, or $10.4 billion, for Onyx. While initially dilutive to earnings, this acquisition provides significant visibility into Amgen's future, with two blockbuster drugs that could eventually generate over $5 billion in annual sales.  Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 21.00
AMGN's P/E(ttm) is ranked higher than
96% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. AMGN: 21.00 )
AMGN' s 10-Year P/E(ttm) Range
Min: 10.4   Max: 42.21
Current: 21

10.4
42.21
P/B 4.27
AMGN's P/B is ranked higher than
79% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 6.41 vs. AMGN: 4.27 )
AMGN' s 10-Year P/B Range
Min: 1.8   Max: 5.24
Current: 4.27

1.8
5.24
P/S 5.42
AMGN's P/S is ranked higher than
87% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 20.67 vs. AMGN: 5.42 )
AMGN' s 10-Year P/S Range
Min: 3.01   Max: 11.84
Current: 5.42

3.01
11.84
PFCF 16.78
AMGN's PFCF is ranked higher than
97% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. AMGN: 16.78 )
AMGN' s 10-Year PFCF Range
Min: 8.78   Max: 49.8
Current: 16.78

8.78
49.8
EV-to-EBIT 18.11
AMGN's EV-to-EBIT is ranked higher than
94% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. AMGN: 18.11 )
AMGN' s 10-Year EV-to-EBIT Range
Min: 8   Max: 30.4
Current: 18.11

8
30.4
PEG 2.41
AMGN's PEG is ranked higher than
97% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. AMGN: 2.41 )
AMGN' s 10-Year PEG Range
Min: 0.25   Max: 2.89
Current: 2.41

0.25
2.89
Shiller P/E 25.41
AMGN's Shiller P/E is ranked higher than
98% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. AMGN: 25.41 )
AMGN' s 10-Year Shiller P/E Range
Min: 12.69   Max: 88.32
Current: 25.41

12.69
88.32
Current Ratio 4.36
AMGN's Current Ratio is ranked higher than
73% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: 4.31 vs. AMGN: 4.36 )
AMGN' s 10-Year Current Ratio Range
Min: 1.31   Max: 6.33
Current: 4.36

1.31
6.33
Quick Ratio 3.99
AMGN's Quick Ratio is ranked higher than
74% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: 3.96 vs. AMGN: 3.99 )
AMGN' s 10-Year Quick Ratio Range
Min: 1.17   Max: 5.75
Current: 3.99

1.17
5.75

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.70
AMGN's Dividend Yield is ranked higher than
75% of the 174 Companies
in the Global Biotechnology industry.

( Industry Median: 1.17 vs. AMGN: 1.70 )
AMGN' s 10-Year Dividend Yield Range
Min: 0.48   Max: 1.89
Current: 1.7

0.48
1.89
Dividend Payout 0.33
AMGN's Dividend Payout is ranked higher than
97% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. AMGN: 0.33 )
AMGN' s 10-Year Dividend Payout Range
Min: 0.22   Max: 0.56
Current: 0.33

0.22
0.56
Yield on cost (5-Year) 1.70
AMGN's Yield on cost (5-Year) is ranked higher than
65% of the 180 Companies
in the Global Biotechnology industry.

( Industry Median: 1.19 vs. AMGN: 1.70 )
AMGN' s 10-Year Yield on cost (5-Year) Range
Min: 0.48   Max: 1.89
Current: 1.7

0.48
1.89
Share Buyback Rate 7.40
AMGN's Share Buyback Rate is ranked higher than
98% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -10.10 vs. AMGN: 7.40 )
AMGN' s 10-Year Share Buyback Rate Range
Min: 8.3   Max: -7.5
Current: 7.4

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 1.07
AMGN's Price/DCF (Projected) is ranked higher than
99% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. AMGN: 1.07 )
AMGN' s 10-Year Price/DCF (Projected) Range
Min: 0.59   Max: 6.23
Current: 1.07

0.59
6.23
Price/Median PS Value 1.24
AMGN's Price/Median PS Value is ranked higher than
80% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 1.97 vs. AMGN: 1.24 )
AMGN' s 10-Year Price/Median PS Value Range
Min: 0.72   Max: 5.18
Current: 1.24

0.72
5.18
Price/Peter Lynch Fair Value 2.28
AMGN's Price/Peter Lynch Fair Value is ranked higher than
97% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. AMGN: 2.28 )
AMGN' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.58   Max: 3.34
Current: 2.28

0.58
3.34
Earnings Yield (Greenblatt) 5.50
AMGN's Earnings Yield (Greenblatt) is ranked higher than
77% of the 469 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. AMGN: 5.50 )
AMGN' s 10-Year Earnings Yield (Greenblatt) Range
Min: 3.3   Max: 12.5
Current: 5.5

3.3
12.5
Forward Rate of Return (Yacktman) 12.78
AMGN's Forward Rate of Return (Yacktman) is ranked higher than
94% of the 757 Companies
in the Global Biotechnology industry.

( Industry Median: -10.00 vs. AMGN: 12.78 )
AMGN' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 1.4   Max: 70.3
Current: 12.78

1.4
70.3

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, GILD, BIIB, CELG, CMXHY » details
Traded in other countries:AMG.Germany, 04332.Hongkong
Amgen Inc., a Delaware corporation was incorporated in 1980. The Company is a biotechnology medicines company. It discovers, develops, manufactures and delivers innovative human therapeutics. Its medicines help patients fight against cancer, kidney disease, rheumatoid arthritis (RA), bone disease, and other serious illnesses. The Company operates in one business segment which includes human therapeutics. The Company's principal products are: Aranesp (darbepoetin alfa) and EPOGEN (Epoetin alfa), erythropoietic-stimulating agents (ESAs) that stimulate the production of red blood cells; Neulasta (pegfilgrastim), a pegylated protein, based on the Filgrastim molecule, and NEUPOGEN (Filgrastim), a recombinant-methionyl human granulocyte colony-stimulating factor (G-CSF), both of which selectively stimulate the production of neutrophils (a type of white blood cell that helps the body fight infection), and Enbrel (etanercept), an inhibitor of tumor necrosis factor (TNF), a substance that plays a role in the body's response to inflammatory diseases. Its marketed products include Sensipar/Mimpara , a small molecule calcimimetic that lowers serum calcium levels; Vectibix , a monoclonal antibody that binds specifically to the epidermal growth factor receptor ; and Nplate, a thrombopoietin receptor agonist that mimics endogenous TPO, the primary driver of platelet production. In addition to its marketed products, it has various product candidates in mid- to late-stage development in a variety of therapeutic areas, including oncology, hematology, inflammation, bone health, nephrology, cardiovascular and general medicine, which includes neuroscience. The Company's manufacturing operations consist of bulk manufacturing, formulation, fill and finish and distribution activities for all of its principal products as well product candidates. Its manufacturing facilities are located in the United States, Puerto Rico and the Netherlands.
» More Articles for AMGN

Headlines

Articles On GuruFocus.com
Weekly 52-Week Highs Highlight: ABT, SWK, LMT, AMGN Sep 13 2014 
After Reaching All-Time Highs, How Can Gilead Sciences Continue growing? Aug 27 2014 
Gulf Resources (GURE) Impressive Performance, Amgen (AMGN) and AstraZeneca (AZN) Positive Data From May 11 2014 
Amgen Inc: As Good as It Gets? Feb 20 2014 
You Can No Longer Ignore Biotech Feb 07 2014 
Mario Gabelli Comments on Amgen Inc. Jan 06 2014 
The Gabelli Asset Fund Shareholder Commentary - Third Quarter Jan 06 2014 
38 Stocks with Higher Dividends Dec 23 2013 
Vanguard Health Care Fund’s Top Third Quarter Holdings Oct 31 2013 
Insiders Are Buying Idera Pharmaceuticals Sep 19 2013 


More From Other Websites
Biotech still place to be: Pro Sep 15 2014
Amgen Announces Results From Several New Exploratory Analyses Evaluating Long-Term Impact Of... Sep 15 2014
New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued... Sep 15 2014
3:17 am Amgen presents analyses of Phase 3 Ivabradine data for the treatment of chronic heart... Sep 15 2014
Amgen Presents Analyses Of Phase 3 Ivabradine Data For The Treatment Of Chronic Heart Failure Sep 14 2014
US STOCKS-Biotech shares drop, Amarin plunges 20 pct Sep 12 2014
Medivation Eyes Blockbuster As Cancer Drug Gets An OK Sep 11 2014
Short Sellers Remain Vigilant Against Biotechs Sep 11 2014
[video] Marathon Oil, Amgen Smart Long Haul Stocks Says Forester Fund Manager Sep 10 2014
Amgen, Inc. Showing More Upside Potential Sep 10 2014
Amgen Announces 23 Abstracts To Be Presented At The American Society for Bone and Mineral Research... Sep 10 2014
Five Reason Amgen Won't Be Breaking Up Sep 08 2014
Amgen To Present At The Morgan Stanley Global Healthcare Conference Sep 05 2014
Amgen Seeks EU Approval for PCSK9 Inhibitor Evolocumab Sep 04 2014
Biotech Stock Roundup: United Therapeutics Up on Court Ruling, Amgen Files PCSK9 Inhibitor Sep 03 2014
Biotech Helps Drive Broad Market Sep 02 2014
Today's Thorns, Roses and All Time Highs in the Markets... Sep 02 2014
[video] The cholesterol race Sep 02 2014
[video] Jim Cramer Says Regeneron is a Better Way to Play it Than Sanofi Sep 02 2014
[video] Biotech's $10 billion opportunity Sep 02 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK